BDBM562782 1-((R)-2-((2S,3R,6S)-2,3-Bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholino)pentanoyl)azetidine-3-carboxylic acid and 1-((S)-2-((2R,3S,6R)-2,3-bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5-oxomorpholino)pentanoyl)azetidine-3-carboxylic acid::US11407721, Example 28

SMILES CCC[C@@H](N1[C@@H]([C@@H](O[C@@H](Cc2ccc(F)cc2)C1=O)c1ccc(Cl)cc1)c1ccc(Cl)cc1)C(=O)N1CC(C1)C(O)=O

InChI Key InChIKey=CAAWFBFPQTYVGS-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 562782   

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562782(US11407721, Example 28 | 1-((R)-2-((2S,3R,6S)-2,3-...)
Affinity DataIC50: 524nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent